An observational study in Cancer, sponsored by Dr. Ersin Arslan Education and Training Hospital. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2021-12-28.
Sponsored by Dr. Ersin Arslan Education and Training Hospital · Observational
Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease. In this study, we aimed to determine the incidence of incidental malignancy in surgical specimens from patients who underwent colectomy for FAP. Prophylactic colectomy should be performed in patients with FAP, as colorectal cancer transformation is inevitable in these individuals. The possibility of incidental cancer identified via histopathological analysis of colectomy specimens should be kept in mind in these patients.
Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease. In this study, we aimed to determine the incidence of incidental malignancy in surgical specimens from patients who underwent colectomy for FAP. The files of patients diagnosed with FAP who underwent surgery in our clinic between 2010 and 2020 were retrospectively reviewed. Definitive surgery was performed in patients with histopathological malignancy identified in colonoscopic biopsies in the preoperative period, while prophylactic surgery was performed in patients without malignancy. The incidence of incidental malignancy in histopathological specimens from patients who underwent prophylactic colectomy was determined. Prophylactic colectomy should be performed in patients with FAP, as colorectal cancer transformation is inevitable in these individuals. The possibility of incidental cancer identified via histopathological analysis of colectomy specimens should be kept in mind in these patients.
90 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.
This study's enrollment of 55 is below the median of 100 across 23 observational studies indexed under Adenomatous Polyposis Coli.
Browse Adenomatous Polyposis Coli studies →Dr. Ersin Arslan Education and Training Hospital is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Familial Adenomatous Polyposis patients
Exclusion Criteria:
familial adenomatous polyposis with incidental cancer
incidental cancer
Familial Adenomatous Polyposis with cancer
Time frame: 2 or 3 week
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Ersin Arslan Education and Training Hospital